OssDsign, a life sciences company commercialising regenerative implant technology from Uppsala University and Karolinska University Hospital, has secured a venture round worth SEK 93m ($10.76m).
SEB Venture Capital and Fouriertransform led the round, with existing backer Karolinska Development (KD), the investment arm of Karolinska Institute, joining in participation. OssDsign, which launched in 2011, last held a round in 2013 worth SEK 13.7m backed by KD.
The company will use the funding to position itself as a global leader in tackling bone defects. OssDsign has already deployed its cranioplasty and facial reconstruction products in Nordic countries, the UK, and Germany, and is planning further expansion across Europe over the course of next year.
Anders Lundqvist, CEO of OssDsign, said: “We today have more than 150 patients treated with OssDsign products in cranial and facial repair, many have been difficult patients on whom competitive techniques have been tried and failed. Our success rate is very high, giving patients improvements in quality of life and hospitals reductions in therapy costs for these costly patient categories. This financing round allows OssDsign to effectively pursue our 2016-2020 plan and we are delighted that our new and existing investors share our vision.”
